Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience

Abstract

Eribulin maintains its activity out of clinical trials, without unexpected toxicities.

Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data

“…1). Two publications were excluded because they were reviews [39,40], two because they were published as abstracts [41,42], four because they were case reports and small series focusing on special clinical scenarios [29][30][31][32], twelve did not report data on older patients subgroup [17][18][19][20][21][22][23][24][25][26][27][28]. Four real-world studies (three retrospective and one observational trial), involving a total of 232 patients, were included in the current analysis.…”

“…A pooled analysis of two single-arm phase 2 studies and one randomized phase 3 study in patients with metastatic breast cancer and good performance status who had received EM monotherapy reported a similar OS, PFS, overall response rate (ORR), clinical benefit rate (CBR) and tolerability in selected patients older than 70 years compared to younger patients [16]. Several recent case series and case reports have addressed the clinical efficacy and safety of EM in patients with advanced breast cancer in real-world practice outside of clinical trials [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32], but few studies have explored outcomes after EM monotherapy in women older than 70 years [33][34][35][36]. We were interested in determining the clinical efficacy and safety of EM in older women with breast cancer.…”

Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes

“…Eribulin was administered for a median of 6 cycles (range, [3][4][5][6][7][8][9][10][11][12][13][14][15]. All the patients reported at least stable disease.…”

“…Given the favorable outcomes and the advantage in overall survival shown with eribulin, the European Commission issued in 2011 a marketing authorization valid throughout the European Union for eribulin for patients with metastatic breast cancer, after anthracycline and taxane treatment. Moreover, other evidence, collected in a field-practice setting, lend further support to the use of eribulin for the treatment of female breast cancer [10][11][12][13][14][15].…”